{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:44:21Z","timestamp":1790959461188,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,2,25]],"date-time":"2020-02-25T00:00:00Z","timestamp":1582588800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007890","name":"University of North Carolina at Chapel Hill","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007890","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.ekir.2020.02.1030","type":"journal-article","created":{"date-parts":[[2020,3,3]],"date-time":"2020-03-03T19:49:49Z","timestamp":1583264989000},"page":"706-717","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Serum Albumin at Partial Remission Predicts Outcomes in Membranous Nephropathy"],"prefix":"10.1016","volume":"5","author":[{"given":"Taewoo","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunro","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline J.","family":"Poulton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vimal K.","family":"Derebail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan L.","family":"Hogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather N.","family":"Reich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald J.","family":"Falk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5890-2862","authenticated-orcid":false,"given":"Patrick H.","family":"Nachman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2020.02.1030_bib1","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1038\/ki.1992.374","article-title":"Predicting chronic renal insufficiency in idiopathic membranous glomerulonephritis","volume":"42","author":"Pei","year":"1992","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2020.02.1030_bib2","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2215\/CJN.04250511","article-title":"Venous thromboembolism in patients with membranous nephropathy","volume":"7","author":"Lionaki","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2020.02.1030_bib3","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/ki.1997.127","article-title":"Validation of a predictive model of idiopathic membranous nephropathy: its clinical and research implications","volume":"51","author":"Cattran","year":"1997","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2020.02.1030_bib4","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.2215\/CJN.01330209","article-title":"The natural history of the non-nephrotic membranous nephropathy patient","volume":"4","author":"Hladunewich","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2020.02.1030_bib5","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1038\/ki.1995.453","article-title":"A\u00a010-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy","volume":"48","author":"Ponticelli","year":"1995","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2020.02.1030_bib6","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1053\/j.ajkd.2005.10.016","article-title":"A\u00a0randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathy","volume":"47","author":"Ponticelli","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2020.02.1030_bib7","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1681\/ASN.2007020166","article-title":"A\u00a0randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy","volume":"18","author":"Jha","year":"2007","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2020.02.1030_bib8","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/sj.ki.5002215","article-title":"Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial","volume":"71","author":"Praga","year":"2007","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2020.02.1030_bib9","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/j.1440-1797.2007.00822.x","article-title":"Prospective controlled study on mycophenolate mofetil and prednisolone in the treatment of membranous nephropathy with nephrotic syndrome","volume":"12","author":"Chan","year":"2007","journal-title":"Nephrol"},{"key":"10.1016\/j.ekir.2020.02.1030_bib10","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/nep.12569","article-title":"Tacrolimus combined with corticosteroids versus Modified Ponticelli regimen in treatment of idiopathic membranous nephropathy: randomized control trial","volume":"21","author":"Ramachandran","year":"2016","journal-title":"Nephrol"},{"key":"10.1016\/j.ekir.2020.02.1030_bib11","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1681\/ASN.2016040449","article-title":"Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up","volume":"28","author":"Dahan","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2020.02.1030_bib12","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1681\/ASN.2015010091","article-title":"Complete and partial remission as surrogate end points in membranous nephropathy","volume":"26","author":"Thompson","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2020.02.1030_bib13","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1111\/j.1523-1755.2004.00873.x","article-title":"Idiopathic membranous nephropathy: definition and relevance of a partial remission","volume":"66","author":"Troyanov","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2020.02.1030_bib14","first-page":"139","article-title":"KDIGO clinical practice guideline for glomerulonephritis","volume":"2","year":"2012","journal-title":"Kidney Int Suppl"},{"issue":"suppl 2","key":"10.1016\/j.ekir.2020.02.1030_bib15","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification","volume":"39","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2020.02.1030_bib16","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.0006-341X.2000.00337.x","article-title":"Time-dependent ROC curves for censored survival data and a diagnostic marker","volume":"56","author":"Heagerty","year":"2000","journal-title":"Biometrics"},{"key":"10.1016\/j.ekir.2020.02.1030_bib17","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1093\/biostatistics\/kxs021","article-title":"Non-parametric estimation of a time-dependent predictive accuracy curve","volume":"14","author":"Saha-Chaudhuri","year":"2013","journal-title":"Biostat"},{"key":"10.1016\/j.ekir.2020.02.1030_bib18","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.kint.2015.12.041","article-title":"Patients with primary membranous nephropathy are at high risk of cardiovascular events","volume":"89","author":"Lee","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2020.02.1030_bib19","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/ki.2011.312","article-title":"Disease-specific risk of venous thromboembolic events is increased in idiopathic glomerulonephritis","volume":"81","author":"Barbour","year":"2012","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2020.02.1030_bib20","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1681\/ASN.2009080861","article-title":"Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy","volume":"21","author":"Polanco","year":"2010","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2020.02.1030_bib21","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1046\/j.1523-1755.2001.0590041484.x","article-title":"Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial","volume":"59","author":"Cattran","year":"2001","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2020.02.1030_bib22","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa1814427","article-title":"Rituximab or cyclosporine in the treatment of membranous nephropathy","volume":"381","author":"Fervenza","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2020.02.1030_bib23","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1093\/ndt\/gfu306","article-title":"Predictors of response and relapse in patients with idiopathic membranous nephropathy treated with tacrolimus","volume":"30","author":"Caro","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2020.02.1030_bib24","unstructured":"Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Guidance for Industry: Expedited Programs for Serious Conditions \u2013 Drugs and Biologics. 2014. Available at: https:\/\/www.federalregister.gov\/documents\/2014\/05\/30\/2014-12534\/guidance-for-industry-on-expedited-programs-for-serious-conditions-drugs-and-biologics-availability. Accessed April 12, 2020."},{"key":"10.1016\/j.ekir.2020.02.1030_bib25","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1681\/ASN.2015111262","article-title":"Membranous nephropathy: quantifying remission duration on outcome","volume":"28","author":"Cattran","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2020.02.1030_bib26","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1038\/ki.2013.476","article-title":"Personalized prophylactic anticoagulation decision analysis in patients with membranous nephropathy","volume":"85","author":"Lee","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2020.02.1030_bib27","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1373\/clinchem.2016.262899","article-title":"State of harmonization of 24 serum albumin measurement procedures and implications for medical decisions","volume":"63","author":"Bachmann","year":"2017","journal-title":"Clin Chem"},{"key":"10.1016\/j.ekir.2020.02.1030_bib28","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1681\/ASN.2013040430","article-title":"Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy","volume":"25","author":"Hoxha","year":"2014","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2020.02.1030_bib29","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ekir.2017.09.001","article-title":"Temporal association between PLA2R antibodies and clinical outcomes in primary membranous nephropathy","volume":"3","author":"Ramachandran","year":"2018","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2020.02.1030_bib30","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1681\/ASN.2014070640","article-title":"Anti-phospholipase A2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy","volume":"26","author":"Ruggenenti","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2020.02.1030_bib31","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.2215\/CJN.11791018","article-title":"High-dose rituximab and early remission in PLA2R1-related membranous nephropathy","volume":"14","author":"Seitz-Polski","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2020.02.1030_bib32","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/ctr.12711","article-title":"Pre-transplant phospholipase A2 receptor autoantibody concentration is associated with clinically significant recurrence of membranous nephropathy post-kidney transplantation","volume":"30","author":"Gupta","year":"2016","journal-title":"Clin Transplant"},{"key":"10.1016\/j.ekir.2020.02.1030_bib33","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1681\/ASN.2014111061","article-title":"Epitope spreading of autoantibody response to PLA2R associates with poor prognosis in membranous nephropathy","volume":"27","author":"Seitz-Polski","year":"2016","journal-title":"J\u00a0Am Soc Nephrol"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024920311037?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024920311037?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T03:30:40Z","timestamp":1762831840000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024920311037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["S2468024920311037"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2020.02.1030","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serum Albumin at Partial Remission Predicts Outcomes in Membranous Nephropathy","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2020.02.1030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}